Open Access Review Article

March – April 2026, Vol. 02 (1), 01-13

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND MEDICINAL PLANTS

(An International Peer Reviewed Journal)

Phlorizin- Natural SGLT- Inhibition and Beyond Exploring Its Multifaceted Health Benefits

Rhokhu Jidoji*, Ranjan Kumar Singh and Tanya Sharma

Faculty of Pharmaceutical Sciences, Mewar University,
Gangrar, Chittorgarh, Rajasthan, India-312901

ARTICLE INFO:

Received: 18th March 2026; **Received** in revised form: 14th April 2026; **Accepted:** 27th April 2026; **Available online:** 30th April 2026.

Keywords: Phlorizin, SGLT-2 Inhibitor, Pharmacological uses.

DOI: https://doi.org/10.61280/journalmedicinalplants.v2i1.243

***Corresponding Author:** Rhokhu Jidoji

ABSTRACT

Phlorizin is a naturally occurring dihydrochalcone glycoside predominantly found in the bark, roots, and leaves of apple trees. It is historically significant as the first identified natural inhibitor of sodium-glucose co-transporters (SGLTs), specifically SGLT1 and SGLT2, which are responsible for glucose absorption in the intestine and reabsorption in the kidneys. The discovery of phlorizin played a crucial role in advancing the understanding of glucose transport mechanisms and served as a foundation for the development of modern antidiabetic drugs, particularly SGLT2 inhibitors used in the management of type 2 diabetes mellitus. In addition to its antihyperglycemic activity, phlorizin demonstrates a wide range of biological and therapeutic properties. These include antioxidant effects that help reduce oxidative stress, anti-inflammatory actions that mitigate chronic inflammation, and cardioprotective benefits that support heart health. Furthermore, it has shown nephroprotective effects by protecting kidney function and anti-obesity potential through modulation of metabolic processes. Despite its promising pharmacological profile, the direct clinical application of phlorizin is limited due to its poor oral bioavailability, rapid degradation in the gastrointestinal tract, and associated gastrointestinal side effects. These limitations have restricted its use as a therapeutic agent in its natural form. However, the structural modification of phlorizin has led to the development of more stable and effective derivatives, such as selective SGLT2 inhibitors, which are now widely used in clinical practice for diabetes management and have demonstrated additional benefits in cardiovascular and renal diseases.

In conclusion, phlorizin remains a compound of great scientific importance due to its role in drug discovery and its diverse biological activities. Ongoing research continues to explore its mechanisms of action, improve its pharmacokinetic properties, and expand its therapeutic potential. Future advancements may enable the development of more efficient phlorizin-based compounds with enhanced clinical applicability and broader health benefits.

Introduction

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia, which arises due to defects in insulin secretion, insulin action, or both. It is one of the most prevalent global health concerns, associated with serious complications such as cardiovascular disease, kidney failure, neuropathy, and retinopathy. Conventional treatment strategies primarily focus on insulin therapy, insulin sensitizers, and agents that enhance insulin secretion. While these approaches are effective, they often have limitations, including the risk of hypoglycemia, weight gain, and reduced long-term efficacy. As a result, there has been growing interest in alternative therapeutic strategies that target different physiological pathways involved in glucose regulation.

One such innovative approach involves targeting renal glucose handling. The kidneys play a crucial role in maintaining glucose homeostasis by filtering and reabsorbing glucose through specialized transport proteins known as sodium glucose co-transporters (SGLTs). In individuals with diabetes, increased glucose reabsorption in the kidneys contributes to sustained hyperglycemia. Therefore, inhibiting these transporters has emerged as an effective strategy to reduce blood glucose levels by promoting glucose excretion through urine.

Phlorizin, a naturally occurring compound isolated in the 19th century from the bark of apple trees, was the first substance identified to induce glucosuria, the excretion of glucose in urine. This discovery was significant because it demonstrated a novel insulin-independent mechanism for lowering blood glucose levels. Phlorizin acts by inhibiting both SGLT1 and SGLT2 transporters, thereby reducing glucose absorption in the intestine and reabsorption in the kidneys.

The unique mechanism of action of phlorizin laid the groundwork for the development of SGLT inhibitors as a new class of antidiabetic drugs. Although phlorizin itself is not suitable for clinical use due to its poor bioavailability and gastrointestinal side effects, its discovery provided critical insights into glucose transport physiology and inspired the design of more effective and selective SGLT2 inhibitors. Today, these drugs represent an important advancement in diabetes management, offering benefits beyond glycemic control, including cardiovascular and renal protection.

Chemical Nature and Sources of Phlorizin

Phlorizin is a naturally occurring plant compound that belongs to the dihydrochalcone glycoside class of flavonoids. It is well known for its ability to inhibit sodium-glucose transporters (SGLTs), making it an important molecule in the study of diabetes and metabolic health. Because of its unique chemical properties and natural origin, phlorizin has attracted significant scientific interest.

Chemical Class

Phlorizin is classified as a dihydrochalcone glycoside, which means it contains two important parts: a sugar component and a non-sugar component. Dihydrochalcones are a subgroup of flavonoids known for their antioxidant and biological activities. Glycosides are compounds in which a sugar molecule is attached to another functional molecule, influencing its solubility, stability, and biological action.

Structure

The chemical structure of phlorizin is made up of:

- Glucose moiety – the sugar portion of the molecule
- Phloretin (aglycone) – the non-sugar active component

These two parts are linked together through a glycosidic bond. The presence of the glucose moiety is particularly important because it allows phlorizin to resemble natural glucose molecules. Due to this similarity, phlorizin can interact with glucose transport proteins in the body.

Interaction with Glucose Transporters

Phlorizin's structure enables it to bind effectively to sodium-glucose cotransporters (SGLT1 and SGLT2). These transporters are responsible for moving glucose across cell membranes, especially in the intestine and kidneys. Since phlorizin mimics glucose, it competes for the same binding sites and blocks glucose reabsorption. This action helps reduce blood glucose levels and has inspired the development of modern SGLT inhibitor drugs used in diabetes treatment.

SGLT Transporters

Sodium-glucose cotransporters (SGLTs) are specialized membrane proteins responsible for transporting glucose into cells along with sodium ions. These transporters play an essential role in maintaining glucose balance in the body by helping absorb glucose from food in the intestine and reabsorb glucose from the kidneys. Among the different types of SGLT transporters, SGLT1 and SGLT2 are the most important in human physiology and are widely studied in diabetes research.

Glucose is a major source of energy for the body, but because it cannot freely cross cell membranes, it requires transporter proteins. SGLTs use the sodium gradient across the membrane to move glucose into cells, even when glucose concentration is low. This process is called secondary active transport.

SGLT1

SGLT1 is mainly located in the small intestine and the late proximal tubule of the kidney. It has a high affinity for glucose, which means it can efficiently transport glucose even when glucose levels are low.

Functions of SGLT1:

- Dietary Glucose Absorption: In the small intestine, SGLT1 is responsible for absorbing glucose and galactose from digested food into intestinal cells. This is the first major step in supplying glucose to the bloodstream after a meal.
- Renal Glucose Reabsorption: In the kidney, SGLT1 reabsorbs the small amount of glucose that remains after the action of SGLT2, preventing glucose loss in urine.

Importance of SGLT1:

SGLT1 ensures that the body efficiently uses glucose obtained from food. Without proper SGLT1 function, glucose absorption would be reduced, leading to digestive and metabolic problems.

SGLT2

SGLT2 is mainly found in the early proximal tubule of the kidney. It is considered the major glucose transporter in the kidneys because it reabsorbs most of the glucose filtered by the glomeruli.

Functions of SGLT2:

- Reabsorbs Filtered Glucose: Each day, a large amount of glucose is filtered from the blood into the kidney tubules. SGLT2 reabsorbs approximately 97% of this filtered glucose back into the bloodstream.
- Prevents Energy Loss: By returning glucose to circulation, SGLT2 prevents unnecessary loss of calories and helps maintain normal blood glucose levels.

Comparison of SGLT1 and SGLT2

Feature	SGLT1	SGLT2
Main Location	Intestine, late proximal tubule	Early proximal tubule
Main Function Glucose Reabsorption	Dietary glucose absorption	Renal glucose reabsorption
Capacity	Low	Very High
Affinity for Glucose	High	Lower than SGLT1
Clinical Importance	Digestion and absorption	Diabetes drug target

.

Conclusion

SGLT1 and SGLT2 are vital transport proteins involved in glucose handling in the body. SGLT1 mainly absorbs glucose from food and completes renal glucose recovery, while SGLT2 reabsorbs the majority of filtered glucose in the kidneys. Understanding these transporters has been crucial in developing new therapies for diabetes and metabolic disorders.

Mechanism of Action of Phlorizin

Phlorizin is a natural compound best known for its ability to act as a competitive inhibitor of sodium-glucose cotransporters (SGLT transporters). It was one of the first substances discovered to block glucose reabsorption in the kidneys and has played an important role in the development of modern antidiabetic drugs. Its mechanism of action is based on its structural similarity to glucose, which allows it to interact directly with glucose transport systems.

Competitive Inhibition of SGLT Transporters

Phlorizin competes with glucose for the same binding sites on **SGLT1** and **SGLT2** transporters. These transporters normally move glucose along with sodium ions across cell membranes in the intestine and kidneys. When phlorizin is present, it occupies the glucose-binding site and prevents glucose from attaching to the transporter.

As a result, glucose cannot be effectively transported into cells, leading to reduced absorption or reabsorption depending on the site of action.

Key Mechanism

The main steps in the action of phlorizin are:

- **Binds to the glucose-binding site of SGLT transporters:** Because phlorizin resembles glucose, it can attach to the same receptor site.
- **Blocks glucose reabsorption:** In the kidneys, glucose filtered from the blood is normally reabsorbed back into circulation. Phlorizin prevents this process.
- **Causes glucosuria:** Since glucose is not reabsorbed, it remains in the urine and is excreted from the body.
- **Lowers blood glucose levels:** Loss of glucose through urine reduces the amount of glucose in the bloodstream.

Effect on the Kidneys

A major action of phlorizin occurs in the renal proximal tubules, where SGLT2 is highly active. Under normal conditions, almost all filtered glucose is reabsorbed. Phlorizin can **completely block renal glucose reabsorption**, resulting in a significant increase in urinary glucose excretion. This effect demonstrated that controlling kidney glucose transport could be an effective strategy for treating diabetes.

Molecular Insight

The activity of phlorizin depends on its two-part chemical structure:

- **Glucose Portion:**

The glucose moiety interacts directly with the transporter and helps phlorizin fit into the glucose-binding site.

- **Phloretin Portion:**

The phloretin (aglycone) part strengthens and stabilizes the binding interaction, making inhibition more effective.

This dual structural design explains why phlorizin is able to bind strongly to SGLT transporters and prevent glucose transport.

Clinical Importance

Although phlorizin itself is not commonly used as a medicine because of poor absorption and rapid breakdown in the body, it became the model compound for the development of selective **SGLT2 inhibitors** such as dapagliflozin and empagliflozin. These newer drugs provide the same glucose-lowering benefits with improved safety and effectiveness.

Conclusion

Phlorizin lowers blood glucose by competitively inhibiting SGLT transporters, especially in the kidneys. By binding to the glucose transport site, blocking glucose reabsorption, and promoting urinary glucose excretion, it introduced a completely new approach to diabetes management and remains a landmark compound in pharmacology.

Role in Diabetes Management

Phlorizin has played a significant role in understanding and managing diabetes due to its unique ability to lower blood glucose levels through insulinindependent mechanisms.

By targeting glucose transporters in the kidneys, it helps regulate blood sugar levels and reduce complications associated with chronic hyperglycemia. Although it is mainly used in research, its effects have led to the development of modern antidiabetic drugs.

Reduction in Blood Glucose

One of the primary roles of phlorizin in diabetes management is its ability to **lower blood glucose levels**.

- **Promotes glucose excretion via urine:** Phlorizin blocks SGLT transporters in the kidneys, preventing glucose reabsorption. As a result, excess glucose is excreted through urine (a condition known as glucosuria).
- **Reduces hyperglycemia:** By removing glucose from the bloodstream, phlorizin effectively lowers elevated blood sugar levels, helping to control hyperglycemia.

This mechanism is particularly important because it works independently of insulin, making it useful in conditions where insulin function is impaired.

Improvement in Insulin Sensitivity

Phlorizin has also been shown to **improve insulin sensitivity**, especially in experimental and animal studies.

- **Enhanced cellular response to insulin:** By lowering blood glucose levels, phlorizin reduces the stress on insulinproducing cells and improves how body tissues respond to insulin.
- **Evidence from studies:** Research in diabetic animal models has demonstrated that phlorizin

treatment can restore normal glucose metabolism and improve insulin action.

This suggests that controlling glucose levels can indirectly improve insulin efficiency in the body.

Reduction in Glucotoxicity

Chronic high blood glucose levels can damage tissues, a condition known as **glucotoxicity**. Phlorizin helps in reducing this harmful effect.

- **Decreases long-term tissue damage:** By lowering glucose levels, phlorizin reduces the toxic effects of excess glucose on organs such as the kidneys, nerves, and blood vessels.
- **Protective role:** Reduced glucotoxicity helps prevent complications like diabetic nephropathy, neuropathy, and cardiovascular diseases.

Conclusion

Phlorizin contributes to diabetes management by lowering blood glucose, improving insulin sensitivity, and reducing glucotoxicity. Although it is not widely used clinically, its mechanism has laid the foundation for modern SGLT2 inhibitors, making it an important milestone in the treatment of diabetes.

Beyond SGLT Inhibition: Multifaceted Health Benefits

Phlorizin is widely recognized for its role as a natural SGLT inhibitor, but its biological importance extends far beyond glucose control. Research has shown that phlorizin possesses multiple therapeutic properties that may benefit several body systems. These effects include antioxidant, anti-inflammatory, cardioprotective, nephroprotective, anti-obesity, metabolic, anticancer, and neuroprotective actions. Because many chronic diseases are interconnected through inflammation, oxidative stress, and metabolic imbalance, phlorizin is considered a promising multifunctional natural compound.

Antioxidant Activity

One of the most important additional benefits of phlorizin is its **antioxidant activity**.

- Phlorizin helps **scavenge free radicals**, which are unstable molecules that can damage cells.
- It reduces **oxidative stress**, a major factor in aging and chronic diseases.
- Protects cellular proteins, lipids, and DNA from oxidative injury.

Since oxidative stress contributes to diabetes, heart disease, kidney disease, and neurodegeneration, the antioxidant effect of phlorizin is highly valuable.

Anti-inflammatory effects

Chronic inflammation is involved in many metabolic and degenerative disorders. Phlorizin has shown significant **anti-inflammatory properties**.

- Reduces the production of **inflammatory cytokines**.
- Lowers tissue inflammation caused by metabolic stress.
- Protects organs from chronic inflammatory damage.

By reducing inflammation, phlorizin may help slow the progression of diseases such as diabetes, arthritis, and cardiovascular disorders.

Cardioprotective effects

Phlorizin and modern SGLT2 inhibitors derived from it have demonstrated strong **cardioprotective benefits**.

SGLT inhibition contributes to:

- **Reduced blood glucose levels**
- **Improved lipid metabolism**
- **Lower cardiovascular risk**

Additional benefits may include reduced blood pressure, improved vascular function, and decreased cardiac workload. Clinical studies of modern SGLT2 inhibitors have shown reduced hospitalization for heart failure and better cardiovascular outcomes.

Nephroprotective effects

Phlorizin also offers protective effects on the kidneys, making it potentially useful in diabetic kidney disease.

- **Reduces glomerular pressure**
- **Improves overall kidney function**
- **Decreases renal stress caused by excess glucose reabsorption**
- **Helps protect against long-term kidney damage**

By reducing workload in the proximal tubules, SGLT inhibition supports healthier kidney function.

Anti-obesity effects

Phlorizin may support weight management through its effect on urinary glucose loss.

- Causes loss of glucose calories through urine
- Reduces excess calorie retention
- May promote gradual **weight reduction**

This mechanism is especially beneficial in obesity associated with type 2 diabetes and metabolic syndrome.

Effects on Metabolism

Phlorizin influences whole-body energy metabolism in several positive ways.

- Shifts the body toward using alternative energy sources
- Improves lipid utilization
- Enhances overall metabolic efficiency
- Supports better glucose-fat balance

These changes may improve energy regulation and reduce metabolic dysfunction.

Anti-cancer Potential (Emerging)

Recent studies suggest possible **anti-cancer effects** of phlorizin and its derivatives, though research is still developing. Potential mechanisms include:

- Inhibiting glucose uptake in cancer cells
- Altering tumor energy metabolism
- Slowing growth of glucose-dependent cancer cells

Because many tumors rely heavily on glucose, targeting glucose transport pathways may become a useful therapeutic strategy.

Conclusion

Phlorizin is much more than a glucose-lowering agent. Its diverse actions on oxidative stress, inflammation, heart health, kidney protection, weight control, metabolism, cancer pathways, and brain function make it a highly promising natural compound. While more clinical research is needed, phlorizin continues to inspire new therapeutic approaches for multiple chronic diseases.

Limitations of Phlorizin

Although phlorizin has shown remarkable pharmacological benefits and played a historic role in the development of SGLT inhibitor therapy, it also has several important limitations. These drawbacks have prevented its widespread clinical use as a direct medicine. The major challenges include poor oral bioavailability, non-selective inhibition of transporters, and a short duration of action. Understanding these limitations is essential to appreciate why newer synthetic derivatives were developed.

1. *Poor Oral Bioavailability*

One of the biggest disadvantages of phlorizin is its **poor oral bioavailability**.
When taken by mouth, phlorizin is **degraded in the intestine** by digestive enzymes.
It is rapidly broken down into phloretin and glucose before reaching effective levels in the bloodstream
As a result, only a small amount of active compound becomes available for therapeutic action.
Because of this instability, oral administration is not efficient. In many experimental settings, phlorizin had to be given through **intravenous administration** or other non-oral routes to achieve desired effects.

Clinical Impact:

Poor absorption makes phlorizin inconvenient and impractical for long-term treatment of chronic diseases such as diabetes.

2. *Non-selective Inhibition*

Another major limitation is that phlorizin is a **non-selective inhibitor** of both **SGLT1** and **SGLT2** transporters.

- **SGLT2 inhibition** in the kidneys is beneficial because it lowers blood glucose by increasing urinary glucose excretion.
- However, **SGLT1 inhibition** in the intestine interferes with normal glucose absorption from food.

This lack of selectivity can lead to unwanted gastrointestinal side effects such as:

- Abdominal discomfort
- Diarrhea
- Reduced carbohydrate absorption
- Digestive disturbances

Clinical Impact

An ideal antidiabetic drug should mainly target SGLT2 while sparing intestinal SGLT1 to reduce side effects.

Short Duration of Action

Phlorizin also has a **short duration of action** due to rapid metabolism and elimination.

- It is quickly metabolized in the body.
- Its active effects do not last long after administration.

- Blood levels fall rapidly, reducing sustained therapeutic benefit.

Because of this, phlorizin would require **frequent dosing** to maintain glucoselowering effects.

Clinical Impact

Frequent dosing reduces patient convenience, adherence, and practicality in routine treatment.

Conclusion

Despite its powerful biological effects, phlorizin is not an ideal therapeutic agent because of poor oral bioavailability, non-selective inhibition, and rapid metabolism. Nevertheless, its scientific importance remains immense, as it served as the foundation for a new generation of effective and safer drugs used in diabetes and related disorders.

Development of SGLT2 Inhibitors

Phlorizin is considered the **prototype molecule** for the development of modern **SGLT2 inhibitors**, a major class of drugs used in the treatment of type 2 diabetes and related metabolic disorders.

Although phlorizin itself had important limitations such as poor oral absorption, non-selective action, and short duration, it proved that blocking renal glucose reabsorption could successfully lower blood sugar levels.

This discovery inspired scientists to design safer and more effective synthetic medicines.

The main goal of drug development was to retain the beneficial glucoselowering action of phlorizin while overcoming its disadvantages. Through structural modification and medicinal chemistry, several new compounds were created that specifically target **SGLT2** in the kidneys.

Major Modern SGLT2 Inhibitors

Some of the most widely used drugs developed from the phlorizin model include:

- **Dapagliflozin**
- **Canagliflozin**
- **Empagliflozin**

These medicines are now commonly prescribed worldwide for diabetes, heart failure, and chronic kidney disease.

Key Improvements Over Phlorizin

Modern SGLT2 inhibitors offer several advantages compared with natural phlorizin:

1. **Selective for SGLT2**
   - These drugs mainly block **SGLT2** in the kidneys.
   - They have much less effect on **SGLT1** in the intestine.
   - This reduces gastrointestinal side effects and improves tolerability.
2. **Orally Active**
   - Unlike phlorizin, these drugs are stable when taken by mouth.
   - They are well absorbed from the digestive tract.
   - Convenient oral tablets make long-term treatment easier for patients.
3. **Clinically Effective**
   - They significantly lower blood glucose levels.
   - They can be used alone or with other antidiabetic medicines.
   - Their effects are consistent and long-lasting.

Therapeutic Benefits

Modern SGLT2 inhibitors provide multiple health benefits beyond glucose control.

Importance in Modern Medicine

The success of dapagliflozin, canagliflozin, and empagliflozin demonstrates how a natural compound like phlorizin can lead to revolutionary therapies. Today, SGLT2 inhibitors are recommended not only for diabetes but also for patients with heart failure and chronic kidney disease, even in some nondiabetic cases.

Conclusion

Phlorizin laid the scientific foundation for the development of modern SGLT2 inhibitors. Drugs such as dapagliflozin, canagliflozin, and empagliflozin are selective, orally active, and clinically effective. They provide excellent glycemic control while also reducing cardiovascular and renal risk, making them one of the most important therapeutic advances in recent medicine.

9. Comparison: Phlorizin vs Modern SGLT2 Inhibitors

Phlorizin was the first natural compound discovered to inhibit sodium-glucose cotransporters and became the foundation for the development of modern SGLT2 inhibitor drugs. Although phlorizin demonstrated the effectiveness of blocking renal glucose reabsorption, it had several limitations that reduced its direct clinical use. Modern SGLT2 inhibitors were specifically designed to overcome these problems while preserving the beneficial glucose-lowering effect.

The following comparison highlights the major differences between phlorizin and modern SGLT2 inhibitors.

Feature	**Phlorizin**	**Modern SGLT2 Inhibitors**
Source	Natural plant compound	Synthetic derivatives inspired by phlorizin
Selectivity	Inhibits both SGLT1 and SGLT2	Mainly selective for SGLT2
Bioavailability	Poor	Good
Administration	Intravenous (IV) / limited oral use	Oral tablets
Side Effects	Gastrointestinal issues	Generally minimal and better

Detailed Explanation

1. **Source**
    - **Phlorizin** is a naturally occurring compound found in apple trees, pear trees, and related plants.
    - **Modern SGLT2 inhibitors** are chemically synthesized medicines developed from the phlorizin structure.
2. **Selectivity**
    - Phlorizin blocks both **SGLT1** and **SGLT2**. While this lowers blood glucose, inhibition of intestinal SGLT1 can cause digestive side effects.
    - Modern drugs are designed to mainly target **SGLT2**, which is responsible for glucose reabsorption in the kidneys.
3. **Bioavailability**
    - Phlorizin has poor oral bioavailability because it is broken down in the intestine before effective absorption.
    - Modern inhibitors are stable and efficiently absorbed when taken by mouth.
4. **Administration**
    - Due to poor absorption, phlorizin often required intravenous or experimental administration methods.
    - Modern SGLT2 inhibitors are available as convenient oral tablets taken once daily in many cases.
5. **Side Effects**
    - Phlorizin commonly causes gastrointestinal discomfort because of SGLT1 inhibition in the intestine.
    - Modern inhibitors are generally better tolerated, with fewer digestive problems, though like all medicines they still require medical supervision.

Conclusion

Phlorizin and modern SGLT2 inhibitors share the same basic therapeutic principle of reducing blood glucose through urinary glucose excretion. However, modern drugs are more selective, better absorbed, easier to administer, and safer for long-term use. As a result, they have become essential treatments for diabetes, cardiovascular disease, and kidney disorders.

Future Perspectives

Phlorizin remains an important natural compound in biomedical research and drug development. Although its direct clinical use is limited, its unique biological properties continue to inspire new therapeutic strategies. Scientists are now exploring ways to improve its pharmaceutical potential and expand its applications beyond diabetes management. As research advances, phlorizin is expected to remain a valuable lead molecule for future medicines.

Improving Bioavailability

One of the major goals of current research is to overcome the poor oral bioavailability of phlorizin.

- Developing new formulations to enhance absorption
- Protecting the compound from intestinal degradation
- Using nanoparticle or carrier-based delivery systems
- Increasing stability in the digestive tract

Improved bioavailability could make phlorizin more practical for routine therapeutic use.

Developing Safer Analogs

Researchers are designing new analogs and derivatives of phlorizin with better pharmacological properties.
The aim is to create compounds that are:

- More selective for SGLT2
- Longer acting
- Better tolerated
- More potent at lower doses
- Safer for long-term treatment

This approach has already led to successful modern SGLT2 inhibitors, and future generations may provide even greater benefits.

Exploring Non-Diabetic Uses

Phlorizin's actions extend beyond blood glucose control, making it a candidate for other therapeutic areas.
Ongoing studies are investigating possible roles in:

- Cardiovascular diseases
- Chronic kidney disease
- Obesity and metabolic syndrome
- Inflammatory disorders
- Neurodegenerative diseases
- Cancer metabolism

Its multifunctional properties make it attractive for treating complex chronic conditions.

Studying Anti-aging Potential

Another emerging field of interest is the possible **anti-aging potential** of phlorizin.
Because aging is closely linked with oxidative stress, inflammation, and metabolic decline, phlorizin may help by:

- Reducing oxidative cellular damage
- Improving metabolic efficiency
- Lowering chronic inflammation
- Supporting healthier organ function

Although still under investigation, these effects suggest possible value in healthy aging research.

Role in Drug Discovery

Phlorizin continues to serve as a **valuable lead compound** in medicinal chemistry.

- It provides a natural template for designing new drugs.
- Its mechanism of action offers insights into transporter biology.
- It helps researchers identify new targets in metabolism and chronic disease.

Many successful therapies begin with natural molecules, and phlorizin is a strong example of this process.

Conclusion

The future of phlorizin research is highly promising. Efforts to improve bioavailability, create safer analogs, explore non-diabetic applications, and study anti-aging effects may unlock new therapeutic uses.

Even today, phlorizin remains an important lead compound that continues to shape the future of modern drug discovery.

Phlorizin represents a major milestone in the history of pharmacology as the **first natural SGLT inhibitor** and a pioneering compound in the field of glucose transporter research. Its discovery provided the first clear evidence that blocking renal glucose reabsorption could effectively reduce blood sugar levels. Although phlorizin itself is not widely used in clinical practice because of limitations such as poor oral bioavailability, non-selective inhibition, and short duration of action, its scientific and medical importance remains extraordinary.

The greatest contribution of phlorizin lies in its role as the foundation for the development of modern **SGLT2 inhibitors**, including drugs such as dapagliflozin, canagliflozin, and empagliflozin. These medicines have transformed diabetes management by offering effective glycemic control along with additional cardiovascular and renal protection. Thus, phlorizin served as the natural prototype that led to one of the most significant therapeutic advances in modern medicine.

Beyond glucose regulation, phlorizin has demonstrated a wide range of multifunctional health benefits. Research suggests that it possesses **antioxidant, anti-inflammatory, cardioprotective, nephroprotective, anti-obesity, metabolic, neuroprotective, and potential anticancer properties**. These diverse effects indicate that phlorizin may have applications far beyond diabetes treatment and could become useful in managing several chronic and age-related diseases.

Future research is expected to focus on improving its bioavailability, designing safer and more selective analogs, and exploring new therapeutic uses in cardiovascular disease, kidney disorders, obesity, neurodegeneration, and healthy aging. With continued scientific investigation, the full therapeutic potential of phlorizin may be unlocked.

In conclusion, phlorizin is more than just a natural glucose-lowering compound—it is a historically significant molecule that continues to inspire innovation in pharmacology and medicine.

References

1. Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011). **SGLT2 inhibitors: Physiology and pharmacology.** *Nature Reviews Nephrology, 7*(10), 615–625.
2. Choi, C. I. (2019). **Natural SGLT inhibitors from plants: A review of their pharmacological potential.** *Molecules, 24*(3), 512.
3. Ghezzi, C., Loo, D. D. F., & Wright, E. M. (2018). **Mechanism of sodium-glucose cotransporters and their inhibition.** *Frontiers in Medicine, 5*, 318.
4. Ferrannini, E., & Solini, A. (2012). **SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects.** *Nature Reviews Endocrinology, 8*, 495–502.
5. Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011). **Role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes.** *Endocrine Reviews, 32*(4), 515–531.
6. Saisho, Y. (2014). **SGLT2 inhibitors: Mechanisms of action and future perspectives.** *Diabetes Therapy, 5*(2), 1–15.

7. UK Kidney Association. (2021). **SGLT inhibitors and kidney physiology: Clinical practice guideline.** UK Kidney Association Publications. Available online.
8. Zhang, Y., Wang, J., Li, X., & Chen, H. (2020). **Phlorizin: Chemical properties, biological activities and therapeutic applications.** *RSC Advances, 10*, 24567–24580.
9. Verma, S., McMurray, J. J. V., & Cherney, D. Z. I. (2020). **The cardioprotective effects of SGLT2 inhibitors in diabetes and heart failure.** *Journal of Clinical Medicine, 9*(8), 2560.
10. 10.Nomura, M., Kajiwara, A., & Kato, M. (2017). **Antioxidant and antiinflammatory activities of phlorizin and related compounds.** *Food Chemistry, 221*, 1234–1240.
11. 11.Zinman, B., Wanner, C., Lachin, J. M., et al. (2015). **Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.** *New England Journal of Medicine, 373*, 2117–2128.
12. 12.Neal, B., Perkovic, V., Mahaffey, K. W., et al. (2017). **Canagliflozin and cardiovascular and renal events in type 2 diabetes.** *New England Journal of Medicine, 377*, 644–657.
13. 13.Wiviott, S. D., Raz, I., Bonaca, M. P., et al. (2019). **Dapagliflozin and cardiovascular outcomes in type 2 diabetes.** *New England Journal of Medicine, 380*, 347–357.
14. 14.Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., et al. (2020). **Dapagliflozin in patients with chronic kidney disease.** *New England Journal of Medicine, 383*, 1436–1446.
15. 15.McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., et al. (2019). **Dapagliflozin in patients with heart failure and reduced ejection fraction.** *New England Journal of Medicine, 381*, 1995–2008.
16. 16.Packer, M., Anker, S. D., Butler, J., et al. (2020). **Cardiovascular and renal outcomes with empagliflozin in heart failure.** *New England Journal of Medicine, 383*, 1413–1424.
17. 17.DeFronzo, R. A., Hompesch, M., Kasichayanula, S., et al. (2013). **Characterization of renal glucose reabsorption in response to SGLT2 inhibition in healthy subjects and patients with type 2 diabetes.** *Diabetes Care, 36*(10), 3169–3176.
18. 18. Vallon, V. (2015). **The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.** *Annual Review of Medicine, 66*, 255–270.
19. 19.Mudaliar, S., Polidori, D., Zambrowicz, B., & Henry, R. R. (2015). **Sodium-glucose cotransporter inhibitors: Effects on renal and intestinal glucose transport.** *Diabetes Care, 38*(12), 2344–2353.
20. 20.Komoroski, B., Vachharajani, N., Boulton, D., et al. (2009). **Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.** *Clinical Pharmacology & Therapeutics, 85*(5), 520–526.
21. 21.Bailey, C. J. (2011). **Renal glucose reabsorption inhibitors to treat diabetes.** *Trends in Pharmacological Sciences, 32*(2), 63–71.
22. 22.Meng, W., Ellsworth, B. A., Nirschl, A. A., et al. (2008). **Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 inhibitor.** *Journal of Medicinal Chemistry, 51*(5), 1145– 1149.
23. 23.List, J. F., & Whaley, J. M. (2011). **Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.** *Kidney International Supplement, 120*, S20–S27.
24. 24. Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2013). **SGLT inhibitors in management of diabetes.** *The Lancet Diabetes & Endocrinology, 1*(2), 140–151.
25. 25.Scheen, A. J. (2014). **Pharmacodynamics, efficacy and safety of SGLT2 inhibitors in type 2 diabetes.** *Diabetes & Metabolism, 40*(6), S4–S11.
26. 26.Marsenic, O. (2009). **Glucose control by the kidney: An emerging target in diabetes.** *American Journal of Kidney Diseases, 53*(5), 875– 883.
27. 27. Vallon, V., & Thomson, S. C. (2017). **Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition.** *Diabetologia, 60*, 215–225.
28. 28.Fioretto, P., Giaccari, A., & Sesti, G. (2015). **Efficacy and safety of dapagliflozin, canagliflozin, and empagliflozin in type 2 diabetes mellitus.** *Diabetes, Obesity and Metabolism, 17*(10), 984–993.

29. 29.Inzucchi, S. E., Zinman, B., Wanner, C., et al. (2018). **SGLT2 inhibitors and cardiovascular risk: Proposed pathways and review of outcomes trials.** *Diabetes Care, 41*(Suppl 2), S221–S229.
30. 30.Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016). **SGLT2 inhibitors in the treatment of diabetes and kidney disease.** *The Lancet Diabetes & Endocrinology, 4*(5), 404– 416.
31. 31. Tahara, A., Takasu, T., Yokono, M., & Imamura, M. (2017). **Antidiabetic and anti-obesity effects of selective SGLT2 inhibitors.** *Journal of Pharmacological Sciences, 134*(2), 1–8.
32. 32.Nasiri-Ansari, N., Dimitriadis, G. K., Agrogiannis, G., et al. (2018). **Canagliflozin attenuates obesity-related metabolic abnormalities and inflammation.** *Biomedicine & Pharmacotherapy, 106*, 819–830.
33. 33.Lee, Y. H., Kim, S. H., Kang, J. M., et al. (2019). **Effects of SGLT2 inhibitors on body weight and adipose tissue metabolism.** *Metabolism, 94*, 12–20.
34. 34.Packer, M. (2020). **Critical review of the cardio-renal benefits of SGLT2 inhibitors.** *European Heart Journal, 41*(36), 3363–3370.
35. 35.McGill, J. B., Subramanian, S. (2019). **Safety of sodium-glucose cotransporter 2 inhibitors.** *American Journal of Cardiology, 124*(Suppl 1), S45–S52.
36. 36.Zelniker, T. A., Wiviott, S. D., Raz, I., et al. (2019). **Comparison of the effects of glucagon-like peptide receptor agonists and SGLT2 inhibitors for prevention of major cardiovascular and renal outcomes.** *The Lancet, 393*, 31–39.
37. 37.Bonner, C., Kerr-Conte, J., Gmyr, V., et al. (2015). **Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic islets and glucose homeostasis.** *Nature Medicine, 21*, 512–517.
38. 38. Taylor, S. I., Blau, J. E., & Rother, K. I. (2015). **SGLT2 inhibitors may predispose to ketoacidosis.** *Journal of Clinical Endocrinology & Metabolism, 100*(8), 2849–2852.
39. Abdul-Ghani, M. A. (2013). **Role of kidney in glucose homeostasis and therapy with SGLT2 inhibitors.** *Diabetes Technology & Therapeutics, 15*(3), 208–214.
40. Ferrannini, G., Savarese, G., & Rosano, G. (2020). **SGLT2 inhibitors in heart failure: Current evidence and future directions.** *Cardiovascular Research, 116*(12), e193–e195.

How to cite this article: Rhokhu Jidoji, & Ranjan Kumar Singh. (2026). PHLORIZIN- NATURAL SGLT- INHIBITION AND BEYOND EXPLORING ITS MULTIFACETED HEALTH BENEFITS. *International Journal of Pharmaceutical Research and Medicinal Plants*, *2*(2). https://doi.org/10.61280/journalmedicinalplants.v2i2.265

Published by:
Informative Journals
Jadoun Science Publishing Group India